MAIA Biotechnology Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
MAIA
- Share Price
-
$1.14
- (As of Thursday Closing)
MAIA Biotechnology General Information
Description
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Contact Information
Website
www.maiabiotech.comCorporate Office
- 444 West Lake Street
- Suite 1700
- Chicago, IL 60606
- United States
Corporate Office
- 444 West Lake Street
- Suite 1700
- Chicago, IL 60606
- United States
MAIA Biotechnology Timeline
MAIA Biotechnology Stock Performance
As of 19-Nov-2026, MAIA Biotechnology’s stock price is $1.14. Its current market cap is $70.4M with 61.8M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.14 | $1.30 | $0.87 - $3.19 | $70.4M | 61.8M | 520K | -$0.47 |
MAIA Biotechnology Financials Summary
As of 30-Sep-2026, MAIA Biotechnology has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 45,260 | 47,655 | 47,117 | 13,846 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (25,728) | (22,710) | (23,573) | (19,801) |
| Net Income | (25,120) | (22,396) | (23,255) | (19,773) |
| Total Assets | 22,101 | 9,705 | 10,155 | 7,567 |
| Total Debt | 0 | 0 | 2,691 | 2,152 |
MAIA Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MAIA Biotechnology Comparisons
Industry
Financing
Details
MAIA Biotechnology Competitors (8)
One of MAIA Biotechnology’s 8 competitors is Candel Therapeutics, a Formerly VC-backed company based in Needham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Candel Therapeutics | Formerly VC-backed | Needham, MA | ||||
| Lantern Pharma | Formerly VC-backed | Dallas, TX | ||||
| Black Diamond Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Pyxis Oncology | Formerly VC-backed | Boston, MA | ||||
| Corvus Pharmaceuticals | Formerly VC-backed | South San Francisco, CA |
MAIA Biotechnology Patents
MAIA Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024370164-A1 | Telomere-targeting phosphatidyl-thio conjugates | Pending | 29-Oct-2023 | ||
| EP-4798601-A1 | Telomere-targeting phosphatidyl-thio conjugates | Pending | 29-Oct-2023 | ||
| US-20250136633-A1 | Telomere-targeting phosphatidyl-thio conjugates | Pending | 29-Oct-2023 | ||
| WO-2025096481-A1 | Telomere-targeting phosphatidyl-thio conjugates | Inactive | 29-Oct-2023 | ||
| WO-2025090539-A1 | Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab | Inactive | 22-Oct-2023 | A61P35/00 |
MAIA Biotechnology Signals
MAIA Biotechnology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
MAIA Biotechnology ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
MAIA Biotechnology FAQs
-
When was MAIA Biotechnology founded?
MAIA Biotechnology was founded in 2018.
-
Where is MAIA Biotechnology headquartered?
MAIA Biotechnology is headquartered in Chicago, IL.
-
What is the size of MAIA Biotechnology?
MAIA Biotechnology has 13 total employees.
-
What industry is MAIA Biotechnology in?
MAIA Biotechnology’s primary industry is Biotechnology.
-
Is MAIA Biotechnology a private or public company?
MAIA Biotechnology is a Public company.
-
What is MAIA Biotechnology’s stock symbol?
The ticker symbol for MAIA Biotechnology is MAIA.
-
What is the current stock price of MAIA Biotechnology?
As of 19-Nov-2026 the stock price of MAIA Biotechnology is $1.14.
-
What is the current market cap of MAIA Biotechnology?
The current market capitalization of MAIA Biotechnology is $70.4M.
-
Who are MAIA Biotechnology’s competitors?
Candel Therapeutics, Lantern Pharma, Black Diamond Therapeutics, Pyxis Oncology, and Corvus Pharmaceuticals are some of the 8 competitors of MAIA Biotechnology.
-
What is MAIA Biotechnology’s annual earnings per share (EPS)?
MAIA Biotechnology’s EPS for 12 months was -$0.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process